Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.__)


Filed by the Registrant x
Filed by a Party other than the Registrant ¨


Check the appropriate box:


¨Preliminary Proxy Statement
¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨Definitive Proxy Statement
xDefinitive Additional Materials
¨Soliciting Material Pursuant to § 240.14a-12


Marker Therapeutics, Inc. 

(Name of Registrant as Specified In Its Charter)



(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)


Payment of Filing Fee (Check the appropriate box)


xNo fee required.
¨Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.


Title of each class of securities to which transaction applies:



Aggregate number of securities to which transaction applies:



Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):



Proposed maximum aggregate value of transaction:



Total fee paid:



¨Fee paid previously with preliminary materials.
¨Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.


Amount Previously Paid:



Form, Schedule or Registration Statement No.:



Filing Party:



Date Filed:

 marker therapeutics registered notice_page001.jpg MARKER THERAPEUTICS, INC. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be Held Virtually on June 8, 2021 You are receiving this communication because you hold shares in the company named above. This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Annual Report and Proxy Statement are available at If you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for a copy. Please make your request for a copy as instructed below on or before May 28, 2021 to facilitate timely delivery. Important information regarding the Internet availability of the company’s proxy materials, instructions for accessing your proxy materials and voting online and instructions for requesting paper or e-mail copies of your proxy materials are provided on the reverse side of this Notice. STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE ANNUAL MEETING. To the Stockholders of MARKER THERAPEUTICS. INC. The 2021 Annual Meeting of Stockholders of Marker Therapeutics, Inc. will be held virtually on June 8, 2021 at 8:00 a.m. Central Time. As a Registered Holder, you may vote your shares at the Annual Meeting of Stockholders by first registering at markertherapeutics/2021/htype.asp and then using your Virtual Control Number below. Your registration must be received by 11:59 p.m. Eastern Time on June 3, 2021. On the day of the Annual Meeting of Stockholders, if you have properly registered, you will log in using the password you received via email in your registration confirmation and follow instructions to vote your shares. Please have your Virtual Control Number with you during the meeting in order to vote. Further instructions on how to attend and vote at the Annual Meeting of Stockholders are contained in the Proxy Statement in the section titled “QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING” - “How do I attend the Annual Meeting?” and “How do I vote?” Voting Items Election of Directors 01 David Eansor02 Steven Elms03 Peter Hoang 04 David Laskow-Pooley05 Frederick Wasserman06 John Wilson07 Juan Vera Approval, on an advisory basis, of the compensation of the Company’s named executive officers. Ratification of the selection by the Audit Commitee of the Board of Directors of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021. The Board of Directors recommends you vote FOR all nominees listed in Proposal 1 and FOR Proposals 2 and 3. The Securities and Exchange Commission rules permit us to make our proxy materials available to our stockholders via the Internet. Material for this annual meeting and future meetings may be requested by one of the following methods: INTERNET TELEPHONE E-MAIL To view your proxy materials online, go to Have your 11 digit Virtual Control Number (located below) available when you access the website and follow the instructions. 877-777-2857TOLL FREE * If requesting material by e-mail, please send a blank e-mail with the company name and your 11 digit Virtual Control Number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material. You must use the 11 digit Virtual Control Number located in the box below. VIRTUAL CONTROL NO. marker therapeutics registered notice_page002.jpg MARKER THERAPEUTICS, INC. 3200 Southwest Freeway, Suite 2500 Houston, TX 77027 PROXY MATERIALS AVAILABLE TO VIEW OR RECEIVE The following proxy materials are available to you for review at: 2020 Annual Report Proxy Statement ACCESSING YOUR PROXY MATERIALS ONLINE Have this notice available when you request a paper copy of the proxy materials or to vote your proxy electronically. You must reference your Virtual Control Number to vote by Internet or request a paper copy of the proxy materials. You May Vote Your Proxy When You View The Materials On The Internet. You Will Be Asked To Follow The Prompts To Vote Your Shares. Your electronic vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated and returned the proxy card. REQUESTING A PAPER COPY OF THE PROXY MATERIALS By telephone please call 1-877-777-2857 or By logging onto or By email at Please include the company name and your Virtual Control Number in the e-mail subject line.